フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee ...
Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...
Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024:...
Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...
Hutchmed (China) Limited 16 October 2024 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response...
Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...
Hutchmed (China) Limited 24 September 2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Approval...
Hutchmed (China) Ltd announced on Friday that it has voluntarily withdrawn its supplemental new drug application for ...
Hutchmed (China) Limited 30 August 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Friday, August 30, 2024:...
Hutchmed (China) Limited 30 August 2024 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Hong Kong, Shanghai...
Hutchmed (China) Limited 22 August 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent...
Hutchmed (China) Limited 06 August 2024 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong...
Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology ...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約